Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
-
Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
-
UPDATE: Canaccord Genuity Assumes Coverage on Cara Therapeutics (CARA) at Buy
-
Cara Therapeutics Reports Second Quarter 2020 Financial Results
-
Cara Therapeutics Reports Second Quarter 2020 Financial Results
-
Cara Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference
-
Cara Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference
-
Cara Therapeutics (CARA) PT Raised to $27 at Canaccord Genuity
-
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Cara Therapeutics (CARA) Prices 4.5M Share Common Offering at $19/Sh
-
Cara Therapeutics Announces Pricing of $85.5 Million Offering of Common Stock
-
Cara Therapeutics Announces Pricing of $85.5 Million Offering of Common Stock
-
Cara Therapeutics (CARA) Announces Proposed 4.5M Share Common Offering
-
Cara Therapeutics Announces Proposed Offering of Common Stock
-
Cara Therapeutics Announces Proposed Offering of Common Stock
-
Cara Therapeutics (CARA) PT Raised to $22 at Canaccord Genuity
-
Cara Therapeutics (CARA) PT Lowered to $21 at Canaccord Genuity
-
Cara Therapeutics (CARA) PT Lowered to $22 at Canaccord Genuity
-
Cara Therapeutics to Webcast Presentation at the Canaccord Genuity 37th Annual Growth Conference
-
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Cara Therapeutics (CARA) Prices 4.45M Shares at $18
-
Cara Therapeutics Announces Pricing of Its Public Offering of Common Stock
-
Cara Therapeutics to Webcast Presentation at Canaccord Genuity 36th Annual Growth Conference
-
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Cara Therapeutics Announces Pricing of Its Public Offering of Common Stock
-
Cara Therapeutics Announces Pricing of Its Public Offering of Common Stock
-
Cara Therapeutics (CARA) Announces $65M Common Stock Offeirng
-
Cara Therapeutics Announces Proposed Offering of Common Stock
-
Cara Therapeutics Announces Proposed Offering of Common Stock
-
Notable Analyst Rating Changes 1/9: (WYNN) (BAH) (EXC) Upgraded; (NUAN) (ABBV) (NBR) Downgraded
-
Pre-Open Stock Movers 01/09: (AGEN) (SD) (YELP) Higher; (WTSL) (CNAT) (ARGS) Lower (more...)
-
Cara Therapeutics (CARA) May Have 'Holy Grail' Alt. to Opiods; Canaccord Starts at Buy
-
UPDATE: Canaccord Genuity Starts Cara Therapeutics (CARA) at Buy
-
Notable Analyst Rating Changes 02/25: (KGC) (ED) (EOG) Upgraded; (PAAS) (VVUS) (BAS) Downgraded
-
Cara Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Over-Allotment Option
-
Cara Therapeutics (CARA) IPO Opens Higher and Gains Momentum
-
Cara Therapeutics Announces Pricing of Initial Public Offering
